X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The research collaboration with CSIRO will help to develop formulations of its small molecule FAK inhibitors, including AMP945 that could be applied topically to wounds and burns to aid healing and reduce scarring.
Lead Product(s): AMP945
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AMP945
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Amplia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 23, 2023
Details:
RECCE® 327 and New RECCE® 529 compounds were selected for their unique mechanisms of action against hyper-mutation, as indicated on bacteria and viruses (respectively).
Lead Product(s): Recce 327
Therapeutic Area: Infections and Infectious Diseases Product Name: Recce 327
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Recce Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
